Novartis Ag (NVS) Receivables (2009 - 2025)

Novartis Ag (NVS) has 14 years of Receivables data on file, last reported at $10.1 billion in Q4 2025.

• Quarterly Receivables rose 18.29% year-over-year to $10.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.1 billion (up 18.29% YoY) and the FY2025 annual result came in at $10.1 billion, up 18.29% from the prior year.
• Receivables improved to $10.1 billion in Q4 2025 per NVS's latest filing, from $9.1 billion in the prior quarter.
• The five-year high for Receivables was $10.1 billion in Q4 2025, with the low at $8.2 billion in Q2 2024.
• Average Receivables over 5 years is $8.8 billion, with a median of $8.7 billion recorded in 2021.
• Year-over-year, Receivables dropped 10.52% in 2024 and rose 18.29% in 2025.
• Novartis Ag's Receivables stood at $8.8 billion in 2021, then climbed by 2.57% to $9.0 billion in 2022, then fell by 7.37% to $8.4 billion in 2023, then grew by 1.93% to $8.5 billion in 2024, then gained by 18.29% to $10.1 billion in 2025.
• Business Quant data shows NVS's Receivables at $10.1 billion in Q4 2025, $9.1 billion in Q2 2025, and $8.5 billion in Q4 2024.